Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Ozempic and other GLP-1 agonist medications have risen in popularity over the last few years due to their touted blood sugar management and weight-loss effects. However, some supplements may not ...

The popularity of Ozempic, Wegovy, and other glucon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in recent years ...

LANGHORNE, PA — Amplity Health shared valuable findings from its latest study on GLP-1 receptor agonist (GLP-1 RA) usage ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...